Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Apr;81(4):1292–1296. doi: 10.1172/JCI113447

Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.

J Y Borg 1, M C Owen 1, C Soria 1, J Soria 1, J Caen 1, R W Carrell 1
PMCID: PMC329661  PMID: 3350974

Abstract

Antithrombin Rouen-II, a new inherited variant of antithrombin-III, was found in two members of a family with no definite history of thrombosis. The subjects had normal antigenic concentrations of antithrombin and normal progressive inhibitory activity. However, the variant had defective heparin and heparan sulfate cofactor activities, and was not activated by a synthetic pentasaccharide representing the minimum heparin sequence. The abnormal antithrombin was isolated using heparin-Sepharose chromatography, and on electrophoresis at pH 8.6 migrated more anodally than normal. Two-dimensional peptide mapping of tryptic and Staphylococcus aureus V8 protease digests was performed and the abnormal peptide was located by tryptophan staining. Amino acid sequence studies demonstrated a substitution of arginine at residue 47 by a serine. Evidence strongly suggests that arginine 47 is a prime heparin binding site in antithrombin and that it forms part of a proposed positively charged linear site (to which heparin binds) that stretches across the surface of the molecule from the A to the D helix.

Full text

PDF
1295

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiach M., Léon M., Michaud A., Capron L. Adaptation of synthetic peptide substrate-based assays on a discrete analyzer. Semin Thromb Hemost. 1983 Jul;9(3):206–216. doi: 10.1055/s-2007-1005022. [DOI] [PubMed] [Google Scholar]
  2. Aiach M., Nora M., Fiessinger J. N., Roncato M., François D., Gelas M. A. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville. Thromb Res. 1985 Sep 1;39(5):559–570. doi: 10.1016/0049-3848(85)90236-1. [DOI] [PubMed] [Google Scholar]
  3. Blackburn M. N., Sibley C. C. The heparin binding site of antithrombin III. Evidence for a critical tryptophan residue. J Biol Chem. 1980 Feb 10;255(3):824–826. [PubMed] [Google Scholar]
  4. Boyer C., Wolf M., Vedrenne J., Meyer D., Larrieu M. J. Homozygous variant of antithrombin III: AT III Fontainebleau. Thromb Haemost. 1986 Aug 20;56(1):18–22. [PubMed] [Google Scholar]
  5. Brennan S. O., George P. M., Jordan R. E. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135. FEBS Lett. 1987 Jul 27;219(2):431–436. doi: 10.1016/0014-5793(87)80266-1. [DOI] [PubMed] [Google Scholar]
  6. Brunel F., Duchange N., Fischer A. M., Cohen G. N., Zakin M. M. Antithrombin III Alger: a new case of Arg 47----Cys mutation. Am J Hematol. 1987 Jun;25(2):223–224. doi: 10.1002/ajh.2830250214. [DOI] [PubMed] [Google Scholar]
  7. Casu B., Johnson E. A., Mantovani M., Mulloy B., Oreste P., Pescador R., Prino G., Torri G., Zoppetti G. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulphates. Arzneimittelforschung. 1983;33(1):135–142. [PubMed] [Google Scholar]
  8. Chang J. Y., Tran T. H. Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem. 1986 Jan 25;261(3):1174–1176. [PubMed] [Google Scholar]
  9. Choay J., Petitou M., Lormeau J. C., Sinaÿ P., Casu B., Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun. 1983 Oct 31;116(2):492–499. doi: 10.1016/0006-291x(83)90550-8. [DOI] [PubMed] [Google Scholar]
  10. Coulondre C., Miller J. H., Farabaugh P. J., Gilbert W. Molecular basis of base substitution hotspots in Escherichia coli. Nature. 1978 Aug 24;274(5673):775–780. doi: 10.1038/274775a0. [DOI] [PubMed] [Google Scholar]
  11. Duchange N., Chasse J. F., Cohen G. N., Zakin M. M. Molecular characterization of the antithrombin III tours deficiency. Thromb Res. 1987 Jan 1;45(1):115–121. doi: 10.1016/0049-3848(87)90263-5. [DOI] [PubMed] [Google Scholar]
  12. Fischer A. M., Beguin S., Sternberg C., Dautzenberg M. D. Comparative effect of heparin and heparan sulphate on two abnormal antithrombin III type 3 variants. Br J Haematol. 1987 Jun;66(2):213–217. doi: 10.1111/j.1365-2141.1987.tb01301.x. [DOI] [PubMed] [Google Scholar]
  13. Koide T., Odani S., Takahashi K., Ono T., Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci U S A. 1984 Jan;81(2):289–293. doi: 10.1073/pnas.81.2.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  15. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984 Aug 15;177(3):531–557. [PubMed] [Google Scholar]
  16. Marcum J. A., Atha D. H., Fritze L. M., Nawroth P., Stern D., Rosenberg R. D. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem. 1986 Jun 5;261(16):7507–7517. [PubMed] [Google Scholar]
  17. Marcum J. A., Fritze L., Galli S. J., Karp G., Rosenberg R. D. Microvascular heparin-like species with anticoagulant activity. Am J Physiol. 1983 Nov;245(5 Pt 1):H725–H733. doi: 10.1152/ajpheart.1983.245.5.H725. [DOI] [PubMed] [Google Scholar]
  18. Marcum J. A., McKenney J. B., Rosenberg R. D. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest. 1984 Aug;74(2):341–350. doi: 10.1172/JCI111429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Marcum J. A., Rosenberg R. D. Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun. 1985 Jan 16;126(1):365–372. doi: 10.1016/0006-291x(85)90615-1. [DOI] [PubMed] [Google Scholar]
  20. Odegård O. R., Lie M., Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis. 1976;5(5):265–275. doi: 10.1159/000214145. [DOI] [PubMed] [Google Scholar]
  21. Owen M. C., Borg J. Y., Soria C., Soria J., Caen J., Carrell R. W. Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His. Blood. 1987 May;69(5):1275–1279. [PubMed] [Google Scholar]
  22. Pecon J. M., Blackburn M. N. Pyridoxylation of essential lysines in the heparin-binding site of antithrombin III. J Biol Chem. 1984 Jan 25;259(2):935–938. [PubMed] [Google Scholar]
  23. Stephens A. W., Thalley B. S., Hirs C. H. Antithrombin-III Denver, a reactive site variant. J Biol Chem. 1987 Jan 25;262(3):1044–1048. [PubMed] [Google Scholar]
  24. Thaler E., Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol. 1981 Jun;10(2):369–390. [PubMed] [Google Scholar]
  25. Wolf M., Boyer C., Lavergne J. M., Larrieu M. J. A new familial variant of antithrombin III: 'antithrombin III Paris'. Br J Haematol. 1982 Jun;51(2):285–295. doi: 10.1111/j.1365-2141.1982.tb02782.x. [DOI] [PubMed] [Google Scholar]
  26. Youssoufian H., Kazazian H. H., Jr, Phillips D. G., Aronis S., Tsiftis G., Brown V. A., Antonarakis S. E. Recurrent mutations in haemophilia A give evidence for CpG mutation hotspots. 1986 Nov 27-Dec 3Nature. 324(6095):380–382. doi: 10.1038/324380a0. [DOI] [PubMed] [Google Scholar]
  27. de Moerloose P. A., Reber G., Vernet P., Minazio P., Bouvier C. A. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity. Thromb Haemost. 1987 Apr 7;57(2):154–157. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES